The "Graft Versus Host Disease Treatment Market Research Report by Disease Type (Acute graft vs. host disease, Chronic graft vs. host disease, and Prophylaxis GVHD), Product, State - United States Forecast to 2027 - Cumulative Impact of COVID-19" report has been added to ResearchAndMarkets.com's offering.

The United States Graft Versus Host Disease Treatment Market size was estimated at USD 332.92 million in 2021, USD 356.77 million in 2022, and is projected to grow at a Compound Annual Growth Rate (CAGR) of 9.14% to reach USD 562.89 million by 2027.

In this report, the years 2019 and 2020 are considered historical years, 2021 as the base year, 2022 as the estimated year, and years from 2023 to 2027 are considered the forecast period.

Cumulative Impact of COVID-19:

The report delivers insights on COVID-19 considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The updated study provides insights, analysis, estimations, and forecasts, considering the COVID-19 impact on the market.

Competitive Strategic Window:

The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies to help the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. It describes the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth during a forecast period.

FPNV Positioning Matrix:

The FPNV Positioning Matrix evaluates and categorizes the vendors in the Graft Versus Host Disease Treatment Market based on Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.

Market Share Analysis:

The Market Share Analysis offers the analysis of vendors considering their contribution to the overall market. It provides the idea of its revenue generation into the overall market compared to other vendors in the space.

It provides insights into how vendors are performing in terms of revenue generation and customer base compared to others. Knowing market share offers an idea of the size and competitiveness of the vendors for the base year. It reveals the market characteristics in terms of accumulation, fragmentation, dominance, and amalgamation traits.

Company Usability Profiles:

• AbbVie Inc.
• Acrofan
• Astellas Pharma Inc.
• Bristol-Myers Squibb Company
• ElsaLys Biotech SA
• F. Hoffmann-La Roche AG
• Johnson & Johnson
• Mallinckrodft PLC
• Merck & Co., Inc.
• Mesoblast Limited
• Neovii Biotech GmbH
• Novartis AG
• Ocugen, Inc.
• Pfizer Inc
• Pluristem Therapeutics Inc.
• Samedan Ltd
• Sanofi SA
• Soligenix, Inc.

Key Topics Covered:

1. Preface

1.1. Objectives of the Study

1.2. Market Segmentation & Coverage

1.3. Years Considered for the Study

1.4. Currency & Pricing

1.5. Language

1.6. Limitations

1.7. Assumptions

1.8. Stakeholders

2. Research Methodology

2.1. Define: Research Objective

2.2. Determine: Research Design

2.3. Prepare: Research Instrument

2.4. Collect: Data Source

2.5. Analyze: Data Interpretation

2.6. Formulate: Data Verification

2.7. Publish: Research Report

2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

5.1. Market Dynamics

5.1.1. Drivers

5.1.2. Restraints

5.1.3. Opportunities

5.1.4. Challenges

5.2. Cumulative Impact of COVID-19

6. Graft Versus Host Disease Treatment Market, by Disease Type

6.1. Introduction

6.2. Acute graft vs. host disease

6.3. Chronic graft vs. host disease

6.4. Prophylaxis GVHD

7. Graft Versus Host Disease Treatment Market, by Product

7.1. Introduction

7.2. Etanercept

7.3. Monoclonal antibodies

7.4. Thalidomide

7.5. Tyrosine kinase inhibitors

7.6. mTOR inhibitors

8. California Graft Versus Host Disease Treatment Market

9. Florida Graft Versus Host Disease Treatment Market

10. Illinois Graft Versus Host Disease Treatment Market

11. New York Graft Versus Host Disease Treatment Market

12. Ohio Graft Versus Host Disease Treatment Market

13. Pennsylvania Graft Versus Host Disease Treatment Market

14. Texas Graft Versus Host Disease Treatment Market

15. Competitive Landscape

15.1. FPNV Positioning Matrix

15.1.1. Quadrants

15.1.2. Business Strategy

15.1.3. Product Satisfaction

15.2. Market Ranking Analysis

15.3. Market Share Analysis, By Key Player

15.4. Competitive Scenario

15.4.1. Merger & Acquisition

15.4.2. Agreement, Collaboration, & Partnership

15.4.3. New Product Launch & Enhancement

15.4.4. Investment & Funding

15.4.5. Award, Recognition, & Expansion

16. Company Usability Profiles

For more information about this report visit https://www.researchandmarkets.com/r/xj8af5

View source version on businesswire.com: https://www.businesswire.com/news/home/20220629005540/en/